Momenta Pharmaceuticals Inc. (MNTA) was a big mover last session, as the company saw its shares rise over 6% on the day. The upside came after Momenta and Sandoz, the generics segment of Novartis AG (NVS), announced FDA approval for the first generic version of multiple sclerosis drug, Copaxone. The news led to far more shares changing hands than in a normal session resulting in solid volume. This reverses the recent trend of the company, as the stock is now trading above the volatile price range of $14.73 to $16.39 in the past one-month time frame.
None of the estimates for this biotechnology stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Momenta Pharmaceuticals currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment